January 20, 2017
Japanese MHLW OK’s Bayer’s cancer drug
Japanese Ministry of Health, Labour and Welfare (MHLW) has granted priority review to Bayer Yakuhin for regorafenib in the second-line…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Asia
January 16, 2017
Chi-Med kicks off two cancer drug studies in China
AIM and Nasdaq listed pharmaceutical company, Hutchison China MediTech Limited (Chi-Med) has initiated two Phase II studies in China for testing cancer treatments.
January 13, 2017
BioGaia’s probiotic to be launched in Thailand
BioGaia has signed an exclusive agreement with Abbott for the rights to commercialize BioGaia products in the area of paediatrics and gastroenterology in Thailand.
January 13, 2017
Norwegian Weifa to sell AFT’s pain and fever drugs in the Nordic region
Weifa has made a deal with New Zealand’s AFT Pharmaceuticals according to which it will sell drugs for pain relief and fever symptoms in the Nordic region (Norway, Sweden, Denmark, Finland and Iceland).
January 12, 2017
Trump says “pharma getting away with murder,” stocks slide
U.S. President-elect Donald Trump on Wednesday said pharmaceutical companies are “getting away with murder” in what they charge the government for medicines, and promised that would change, sending drugs stocks sharply lower.
January 11, 2017
Premaitha closes deal on Yourgene acquisition
Premaitha Health’s shareholders have approved the acquisition of Yourgene, a bioinformatics specialist based in Taiwan. The purchase was approved on Tuesday afternoon.
January 11, 2017
UPDATE: Omega starts selling malaria tests in India
Food allergy focused medical diagnostic company Omega has gotten ISO certification for the Quality Management System for its Asian subsidiary in India, and it started with the domestic sales of its products.
January 10, 2017
Japanese Takeda in a $5.2 billion acquisition deal with USA-based Ariad
Takeda has ensured the signature to buy USA-based drugmaker focused on producing cancer treatments, Ariad Pharmaceuticals for about $5.2 billion, or $24 per share in cash for stockholders.
January 5, 2017
Lilly mixes managers, reduces U.S. staff due to Solanezumab test fail
Eli Lilly begins new year with reorganizing its leadership structure to pursue better growth opportunities in the upcoming years. The Chief Executive Officer of Lilly, David A. Ricks, who’s new position is also one among the latest promotions, said that the changes made to pharmaceutical therapeutics and geographic business should simplify and maximize the company’s late-stage pipeline and new drugs, as well as to improve productivity.
December 30, 2016
Corporate makeovers drive corporate takeovers in 2016 M&A bonanza
In 2016, mega deals became ever more transformative.
German drug and crop chemical maker Bayer AG announced its $66 billion takeover of U.S. agrochemicals company Monsanto Co, while ChemChina signed a $43 billion acquisition of Swiss seeds group Syngenta AG, as consolidation in the sector intensified.